Thema: US31572Q8814
KYNB, US31572Q8814
chart-840332.jpg - Foto: THN
Kyntra Bio stock stays in focus as oncology milestones approach
Kyntra Bio stock remains in focus as the company advances oncology and rare-disease programs. Key clinical milestones are expected later in 2026.
ad-hoc-news.de, heute 00:20 Uhr
KYNB, US31572Q8814
Kyntra Bio stock: Maxim initiates coverage for Kyntra Bio ...
Maxim set a USD 35.00 target on October 13, 2026. Kyntra Bio stock faces a Nasdaq test requiring USD 50.00 million for each threshold.
ad-hoc-news.de, 23.10.26 03:30 Uhr
KYNB, US31572Q8814
Kyntra Bio stock gains 16.83 percent to EUR 4.72 at Lang ...
Nasdaq review may last 180 days. Kyntra Bio stock costs EUR 4.72 on October 20, 2026, up 16.83 percent versus the Frankfurt close.
ad-hoc-news.de, 20.10.26 22:03 Uhr
KYNB, US31572Q8814
Kyntra Bio stock fell to USD 4.85 on October 16 down 9.5 ...
Maxim set a USD 35.00 target on October 13, 2026. Kyntra Bio stock stood at USD 4.85 on October 16, 2026, down 9.5 percent on Nasdaq.
ad-hoc-news.de, 17.10.26 19:34 Uhr
KYNB, US31572Q8814
Kyntra Bio stock costs EUR 5.00 at a USD 22.6 million market ...
Its range was USD 5.34 to USD 11.65 on October 15, 2026. Kyntra Bio stock costs EUR 5.00 on October 15, 2026, up 0.45 percent on Nasdaq.
ad-hoc-news.de, 15.10.26 19:05 Uhr
KYNB, US31572Q8814
Kyntra Bio sought Nasdaq review and Kyntra Bio stock costs ...
Nasdaq requires USD 50.00 million in assets and revenue. Kyntra Bio stock costs EUR 5.45 on October 8, 2026 after EUR 5.53.
ad-hoc-news.de, 08.10.26 10:51 Uhr
KYNB, US31572Q8814
Kyntra Bio appoints Singer and Kyntra Bio stock matches ...
